



**HAL**  
open science

# **Inhibition of store-operated calcium channels by N-arachidonoyl glycine (NAGly): no evidence for the involvement of lipid-sensing G protein coupled receptors**

Aykut Deveci, Jessy Hasna, Alexandre Bouron

## ► To cite this version:

Aykut Deveci, Jessy Hasna, Alexandre Bouron. Inhibition of store-operated calcium channels by N-arachidonoyl glycine (NAGly): no evidence for the involvement of lipid-sensing G protein coupled receptors. *Scientific Reports*, 2020, 10 (1), <10.1038/s41598-020-59565-4>. <hal-03005881>

**HAL Id: hal-03005881**

**<https://hal.science/hal-03005881v1>**

Submitted on 17 Nov 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



HAL Authorization

**Inhibition of store-operated calcium channels by N-arachidonoyl glycine (NAGly): no evidence  
for the involvement of lipid-sensing G protein coupled receptors**

Aykut DEVECI<sup>1</sup>, Jessy HASNA<sup>1</sup>, Alexandre BOURON<sup>1\*</sup>

<sup>1</sup> Université Grenoble Alpes, CNRS, CEA, IRIG-LCBM, 38000 Grenoble, France.

\* Present address:

Genetics and Chemogenomics

UMRS-1038 INSERM-CEA-UGA

CEA

17 rue des Martyrs

38054 Grenoble

FRANCE

Phone : 00.33.438.785.258

E-mail : [alexandre.bouron@cea.fr](mailto:alexandre.bouron@cea.fr)

**Running Title:** Direct inhibition of SOCE by NAGly

## **Abstract**

N-arachidonoyl glycine (NAGly) is an endogenous lipid deriving from the endocannabinoid anandamide (AEA). Identified as a ligand of several G-protein coupled receptors (GPCRs), it can however exert biological responses independently of GPCRs. NAGly was recently shown to depress store-operated  $\text{Ca}^{2+}$  entry (SOCE) but its mechanism of action remains elusive. The major aim of this study was to gain a better knowledge on the NAGly-dependent impairment of SOCE in neurons of the central nervous system (CNS) from mice. First, we examined the expression of genes encoding for putative lipid sensing GPCRs using transcriptomic data publicly available. This analysis showed that the most abundant GPCR transcripts present in the cerebral cortices of embryonic brains were coding for lysophosphatidic acid (LPA) and sphingosine-1 phosphate (S1P) receptors. Next, the presence of functional receptors was assessed with live-cell calcium imaging experiments. In primary cortical cells S1P and LPA mobilize  $\text{Ca}^{2+}$  from internal stores via a mechanism sensitive to the S1P and LPA receptor antagonists Ex26, H2L5186303, or Ki16425. However, none of these compounds prevented or attenuated the NAGly-dependent impairment of SOCE. We found no evidence for the requirement of lipid sensing GPCRs in this inhibitory process, indicating that NAGly is an endogenous modulator interfering with the core machinery of SOCE. Moreover, these data also raise the intriguing possibility that the depression of SOCE could play a role in the central effects of NAGly.

**Keywords:** cortex; calcium channels; cannabinoids; calcium signaling; store-operated Ca entry;

## Introduction

N-arachidonoyl glycine (NAGly) is a lipid deriving from the endocannabinoid anandamide (AEA). It is naturally present in various tissues and organs like the brain<sup>1,2</sup> but the physiological functions exerted by NAGly in the neural system are not yet fully characterized. This endogenous bioactive molecule influences pain perception and displays analgesic properties<sup>1,3-5</sup>. This led to the hypothesis that NAGly could be a natural modulator of pain<sup>6</sup>. The analgesic actions of NAGly have been studied principally on dorsal root ganglia (DRG) neurons and dorsal horn neurons from spinal cord slices<sup>7</sup>. For instance, NAGly inhibits low threshold voltage-gated  $\text{Ca}^{2+}$  channels (Cav3) in DRG neurons<sup>8</sup> and the glycine uptake transporter GLYT2 in dorsal horn neurons, which contributes to enhance inhibitory glycinergic synaptic transmission in these cells<sup>7</sup>. NAGly has also been shown to depress excitatory NMDA-dependent synaptic transmission<sup>7</sup>. The effects of NAGly on neurons of the brain have however been much less characterized. In primary cortical neurons NAGly releases  $\text{Ca}^{2+}$  from the endoplasmic reticulum (ER), potentiates the passive leakage of  $\text{Ca}^{2+}$  out of the ER, and impairs the store-operated  $\text{Ca}^{2+}$  entry (SOCE)<sup>9</sup>.

One key issue when addressing the question of the cellular effects of NAGly is to determine whether it interferes directly with the activity of its targets or recruits dedicated G-protein coupled receptors (GPCRs) linked to downstream intracellular signaling cascades. NAGly has been proposed to act as an agonist of some orphan GPCRs like GPR18<sup>10</sup>, GPR55<sup>11</sup>, and GPR92<sup>12</sup>. It is however worthy of note that NAGly can influence the activity of some effectors without the requirement of GPCRs. This is for instance the case for the NAGly-dependent regulation of voltage-gated  $\text{Ca}^{2+}$  channels and  $\text{Na}^+/\text{Ca}^{2+}$  exchanger activity<sup>8,13,14</sup>.

SOCE is an important physiological  $\text{Ca}^{2+}$  route of the plasma membrane. It is activated in response to the depletion of the ER  $\text{Ca}^{2+}$  stores<sup>15</sup> and involves distinct actors: stromal interacting molecules (STIM1-2) and Orai1-3 channels<sup>16-18</sup>. STIM are ER resident proteins that seem to function as  $\text{Ca}^{2+}$  sensors<sup>19</sup>. The depletion of the ER  $\text{Ca}^{2+}$  stores governs the molecular interaction between STIM and plasma membrane  $\text{Ca}^{2+}$  channels of Orai type that are responsible for the SOCE response<sup>17,18</sup>. Recent studies identified NAGly as a potent inhibitor of SOCE in various cell lines (NIH-3T3 fibroblasts, human endothelial cell line EA.hy926, rat pancreatic  $\beta$ -cell line INS-1 832/13, rat basophilic leukemia cell line RBL-2H3) and in primary cultured neural cells<sup>9,20,21</sup>. Two hypotheses were put forward to explain the NAGly-dependent depression of SOCE<sup>20</sup>: 1) direct disruption of the coupling between STIM and Orai, or 2) recruitment of an intracellular signalling cascade activated downstream to NAGly-sensitive receptors and regulating negatively SOCE activity. The aim of the present work was to verify whether a lipid sensing GPCR is contributing to the NAGly-induced impairment of SOCE in

cortical neurons. First, we analyzed a recent publicly available transcriptomic dataset obtained by RNAseq<sup>22</sup> to characterize the expression of genes encoding for putative lipid sensing GPCRs in the cerebral cortices of embryonic mice. The most abundant transcripts were coding for lysophosphatidic acid (LPA) and sphingosine-1 phosphate (S1P) receptors. After having checked the presence of functional receptors, the contribution of LPA and S1P receptors to the NAGly-dependent inhibition of SOCE was evaluated using a pharmacological approach.

## **Material and methods**

### **Animal and Ethical statement**

C57Bl6/J (stock #000664) mice were obtained from the Jackson Laboratory (USA). They were housed in a temperature-controlled room under a 12 h light - 12 h dark cycle with ad libitum access to food and water. An environmental enrichment consisting in the addition of tunnels was provided for all animals in accordance with the Animal Welfare Committee of the CEA Grenoble. Experimental procedures were approved by the animal care committee of the CEA's Life Sciences Division (CETEA, A14-006). Experiments were conducted in compliance with the French legislation and the European Community Council Directive of 24 November 1986 (86/609/EEC).

### **Primary cultures of cortical neurons**

Cells were dissociated from cerebral cortices collected from embryonic (E13) mice (with the vaginal plug as E0) according to<sup>9,23,24</sup>. Briefly, tissues were placed in a 1.5 mL Eppendorf tube containing 1 mL of an ice-cold  $\text{Ca}^{2+}$ - and  $\text{Mg}^{2+}$ -free Hank's solution supplemented with 33 mM glucose, 4.2 mM  $\text{NaHCO}_3$ , 10 mM HEPES, and 1% penicillin/streptomycin. Cells were isolated by a mechanical trituration of the medium containing the cerebral cortices. The cell suspension was filtered through a 40- $\mu\text{m}$  cell strainer before plating the cells on 16 mm  $\varnothing$  glass coverslips. They were kept in a Neurobasal medium supplemented with B27 (2%) and glutamine (500  $\mu\text{M}$ ) and maintained in a 5%  $\text{CO}_2$  atmosphere at 37°C. All the experiments were conducted on cells kept 2 or 3 days *in vitro*.

### **Calcium imaging experiments with Fluo-4**

The culture medium was removed and replaced by a saline containing (in mM) 150 NaCl, 5 KCl, 1  $\text{MgCl}_2$ , 2  $\text{CaCl}_2$ , 5.5 glucose, 10 HEPES (pH 7.4, NaOH). LPA- and S1P-induced  $\text{Ca}^{2+}$  responses were analyzed with Fluo-4. Cells were incubated with 5  $\mu\text{M}$  Fluo-4/AM for 20 min following procedures described previously<sup>23,24</sup>. Images were obtained by a CCD CoolSnap HQ2 camera (Princeton Instruments, Roper Scientific, France) mounted on an inverted Zeiss A1 microscope (Carl Zeiss, France). Cells were excited at 470 nm and emission was collected at 525 nm using a DG-4 wavelength switcher (Princeton Instruments, Roper Scientific, France). MetaFluor (Universal Imaging, Roper Scientific, France) was used for image acquisition and analysis. All experimental procedures were conducted at room temperature. Time-lapse changes in Fluo-4 fluorescence intensity were collected at a frequency of 0.2 Hz from 30-45 cell bodies per dish and analyzed off-line by defining regions of measurements. Results were expressed as  $F/F_0$ , with  $F$  being the fluorescence at each time point and  $F_0$  being the mean baseline fluorescence that was monitored at the beginning of each experiment for 1 min before the addition of any substance. Culture dishes were discarded at the end of the recording and never re-used. A positive LPA (or S1P)-induced calcium response was determined as one  $F/F_0$

greater than 0.02 that develops within 50 s upon the application of the agonist. Fluo-4 responses were measured as area under curve (AUC).

### **Calcium imaging experiments with Fura-2**

The fluorescent  $\text{Ca}^{2+}$  probe Fura-2 was used to study store-operated  $\text{Ca}^{2+}$  entry (SOCE). The experimental conditions and setup were as above except that cells were incubated with 2.5  $\mu\text{M}$  Fura-2 for 20 min at room temperature. They were then washed twice and kept in a Fura-2-free saline solution for >12 min at room temperature. A dual excitation at 340 and 380 nm was used and emission was collected at 515 nm. Images were acquired at a frequency of 0.2 Hz and analyzed off-line. The classical “ $\text{Ca}^{2+}$  add-back” protocol was used to study SOCE. Cells were bathed in a nominally  $\text{Ca}^{2+}$ -free saline containing (in mM) 150 NaCl, 5 KCl, 3  $\text{MgCl}_2$ , 5.5 glucose, 10 HEPES (pH 7.4, NaOH). SOCE activation was triggered by depletion of the ER  $\text{Ca}^{2+}$  pool with 200 nM thapsigargin, which induced a transient elevation in intracellular  $\text{Ca}^{2+}$  concentration before re-admission of 2 mM external  $\text{Ca}^{2+}$ . SOCE responses were analyzed in cells generating a rapid  $\text{Ca}^{2+}$  rise upon the application of a depolarizing saline containing 90 mM KCl. In cultures of embryonic cortical cells, KCl responding cells are identified as neurons whereas KCl-unresponding cells are considered as non-neuronal cells<sup>25</sup>. The depolarizing ( $\text{K}^+$  rich) medium had the following composition (in mM): 65 NaCl, 90 KCl, 1  $\text{MgCl}_2$ , 2  $\text{CaCl}_2$ , 5.5 glucose, 10 HEPES (pH 7.4, NaOH).  $\text{Ca}^{2+}$  changes as a function of time were expressed as delta ratio F340/F380 whereas total  $\text{Ca}^{2+}$  responses were measured as area under curve (AUC).

Stock solutions of Ex26, Ki16425, and BTP2 were prepared in dimethyl sulfoxide (DMSO). Methanol and ethanol were used for preparing stock solutions of SIP and NAGly, respectively. These stock solutions were diluted at least 1000-fold into the recording saline immediately before use so that the final concentration of vehicle never exceeded 0.1%. Control experiments were performed with DMSO, ethanol and methanol alone. None of the solvent altered cytosolic  $\text{Ca}^{2+}$  signals, at least at the concentrations used.

### **Analysis of gene expression by RNAseq**

The RNASeq gene expression data derive from<sup>22</sup>. Raw fastq files are publicly available and can be found on the GEO repository under accession number: GSEXXX.

### **Data and Statistical analysis**

Each experimental condition as well as its appropriate control were tested on the same batch of primary neuronal cell cultures. For the  $\text{Ca}^{2+}$  imaging experiments, all experiments were done  $\geq 3$  times (e.g. with  $\geq 3$  distinct biological samples) using distinct dishes from different batches of cells (e.g. from distinct pregnant mice). Data are presented as means  $\pm$  standard error of the mean (SEM) with  $n$  being the number of biological replicates. SigmaPlot (version 10.0, Systat Software) and SigmaStat (version

3.5, Systat Software) were used for plotting graphs and statistical analysis, respectively. Differences between several groups of cells were tested using one-way analysis of variance (ANOVA) followed by a Bonferroni's *post hoc* test. A *P* value <0.05 was considered statistically significant.

### **Materials**

Fluo-4/AM, Fura-2 and tissue culture media were from Molecular Probes (Invitrogen, France). N-arachidonoyl glycine (NAGly) was from Tocris (Bio-Techne, France). All the other reagents were obtained from Sigma-Aldrich (France).

## Results

### mRNA expression of lipid sensing GPCRs in the cerebral cortex of embryonic mice

In order to determine whether NAGly is acting via a GPCR, we analyzed the expression of genes encoding for putative lipid sensing GPCRs in the embryonic cerebral cortex. Table 1 provides the list of the 60 mouse genes selected<sup>26-30</sup>. The transcriptomic data were extracted from a recent RNAseq study<sup>22</sup>. The expression pattern of putative lipid sensing GPCRs was analyzed at 3 embryonic ages: E11, E13 and E17. Only genes for which the number of transcripts per million (TPM) was >2 were considered as significantly expressed<sup>31</sup>, therefore when the number of transcripts was <2 TPM, the gene was eliminated from the analysis. This resulted in the selection of 14 genes encoding for putative lipid sensing GPCRs (Figure 1). In this RNAseq analysis the genes encoding for GPR18, GPR55 and GPR92, 3 putative targets of NAGly, were not expressed. Overall, the most abundant transcripts were coding for cannabinoid receptors type 1 (CB<sub>1</sub>) (Cnr1 gene), the orphan receptor GPR12, lysophosphatidic acid (LPA) and sphingosine-1 phosphate (S1P) receptors (Figure 1). Of note, the abundance of CB<sub>1</sub> and GPR12 transcripts increased markedly during the embryonic development of the cerebral cortex whereas the expression of genes encoding for LPA and S1P receptors was repressed. Since all the live-cell Ca<sup>2+</sup> imaging reported previously were conducted on cortical cells isolated from E13 brain cerebral cortices<sup>9</sup> we focused our attention on the most expressed lipid sensing GPCR genes at that embryonic age: S1pr1, Lpar2 and Lpar6 (vertical arrows, Figure 1). They encode for S1P1, LPA2 and LPA6 receptors, respectively. CB<sub>1</sub> was excluded from our analysis because NAGly has no affinity for CB<sub>1</sub> receptors<sup>32</sup> and the CB<sub>1</sub> antagonist AM251 did not prevent the NAGly-induced responses in cortical neurons<sup>9</sup>, arguing against a role for these receptors. On the other hand, GPR12 was also not considered as a likely target of NAGly because the GPR12 gene was weakly expressed at E13 (Figure 1). Its expression was strongly upregulated but only at the end of corticogenesis (E17).

### Presence of functional LPA and S1P receptors

The activation of S1P and LPA receptors mobilizes Ca<sup>2+</sup> from internal stores<sup>33-36</sup>. We thus performed live-cell Ca<sup>2+</sup> imaging fluorescent microscopy experiments with Fluo-4 to assess the presence of functional S1P and LPA receptors. Several cell populations are present in the primary cultures. For instance, 80-85% of the cells express  $\beta_{III}$ -tubulin (a marker of post-mitotic neurons) and possess voltage-gated Ca<sup>2+</sup> channels<sup>42,43</sup>, indicating that most cells display a post-mitotic neuronal phenotype. First, the presence of functional LPA and S1P receptors was assessed in the entire cell population. LPA (10  $\mu$ M, Figure 2A) and S1P (10  $\mu$ M, Figure 2C) evoked prominent Ca<sup>2+</sup> rises in  $\square$ 15% (61/416 cells) and  $\square$ 13% (39 out of 303) of the cells tested, respectively. The LPA-induced Ca<sup>2+</sup> signals were partially blocked by 10  $\mu$ M H2L5186303, a selective LPA<sub>2/3</sub> receptor antagonist<sup>37</sup>, and nearly completely suppressed by 10  $\mu$ M Ki16425, a LPA<sub>1/2/3</sub> receptor antagonist<sup>37-40</sup> (Figure 2B). The

percentage of cells responding to LPA was 12% (29/238 cells) and <1% (1/169 cells) with H2L5186303 and Ki16425, respectively. Therefore, H2L5186303 diminished the peak of the  $\text{Ca}^{2+}$  rise without affecting the number of LPA responsive cells whereas Ki16425 affected both parameters. The  $\text{S1P}_1$  receptor antagonist Ex26 (1  $\mu\text{M}$ )<sup>41</sup> reduced the peak amplitude of the S1P-induced  $\text{Ca}^{2+}$  signals and diminished the number of responsive cells with only 12 cells out 220 tested ( $\square$ 5%) generating a  $\text{Ca}^{2+}$  signal in response to 10  $\mu\text{M}$  S1P (Figure 2D). In each instance, depleting the ER with thapsigargin prevented the development of a  $\text{Ca}^{2+}$  rise upon LPA or S1P application (Figures 2B, D).

Previous reports showed that LPA and S1P receptors are mainly found in proliferative regions of the immature cerebral cortex, with few post-mitotic neurons responding to LPA and S1P<sup>35</sup>. This latter point was checked by using a depolarizing saline solution containing 90 mM KCl to evoke KCl-dependent  $\text{Ca}^{2+}$  rises. Acutely cultured cells were undifferentiated cells. When cultured for several days, some of these differentiate into neurons (post-mitotic) responding to high- $\text{K}^+$  whereas non-differentiated cells are not high- $\text{K}^+$  sensitive. In cultures of embryonic cortical cells, KCl responding cells are identified as neurons whereas KCl-unresponsive cells are considered as non-neuronal cells<sup>25</sup>. **Overall, only 10 of 67 LPA sensitive cells ( $\square$ 15%) generated an intracellular  $\text{Ca}^{2+}$  rise in response to KCl. These data are consistent with a previous report showing that in the embryonic cerebral cortex LPA receptors are predominantly expressed by neural precursor cells with only a small minority of neurons responding to LPA<sup>35</sup>. On the other hand, 5 of 25 S1P sensitive cells (20 %) were KCl-responsive cells. This indicates that the S1P-sensitive cells are also mainly found in KCl-insensitive cells<sup>34</sup>.** Taken together, LPA or S1P mobilizes  $\text{Ca}^{2+}$  from the ER in a subset of cells (<20%). These functional LPA- and S1P-sensitive receptors are essentially expressed by non-neuronal cells<sup>35,44</sup>.

Before testing the contribution of LPA and S1P receptors in the NAGly-dependent alteration of SOCE, it was important to check whether the receptor antagonists Ki16425 and Ex26 could alter SOCE on their own. In the following experiments, the ratiometric  $\text{Ca}^{2+}$  probe Fura-2 was used to analyze SOCE in cells that responded to the KCl challenge (i.e. post-mitotic neurons). Cells, bathed in a nominally  $\text{Ca}^{2+}$ -free medium, were challenged with thapsigargin to deplete ER  $\text{Ca}^{2+}$  stores. A subsequent re-admission of external  $\text{Ca}^{2+}$  was followed by an intracellular elevation of  $\text{Ca}^{2+}$  (open circles, Figure 3A)<sup>9,24</sup>. This entry of  $\text{Ca}^{2+}$  was sensitive to the CRAC channel blocker BTP2<sup>45,46</sup> (1  $\mu\text{M}$ , gray up triangles, Figure 3A). The thapsigargin-evoked  $\text{Ca}^{2+}$  release was unaffected by Ex26 (1  $\mu\text{M}$ , filled down triangles) or Ki16425 (10  $\mu\text{M}$ , gray squares) (Figure 3A). The SOCE response was however upregulated by Ki16425 but not by Ex26. This is further illustrated in Figure 3B showing the  $\text{Ca}^{2+}$  release and entry analyzed as area under the curve for each condition tested. Ki16426 enhanced the SOCE signal by  $\square$ 30% (n=5, p<0.05) (Figure 3B, gray bar). Altogether, these data show that the

LPA and S1P receptor antagonists used did not alter the ER  $\text{Ca}^{2+}$  release. The SOCE response was also unaffected by Ex26 but augmented by Ki16426. This potentiating effect was not investigated further.

### **NAGly depresses SOCE independently of LPA and S1P receptors**

After having shown the presence of functional receptors sensitive to LPA and S1P, their involvement in the NAGly-induced impairment of SOCE was considered. In the following set of experiments, Fura-2-loaded cells were first stimulated with a  $\text{K}^+$ -rich saline (90 mM KCl) before recording SOCE responses in neurons (i.e. in KCl-responsive cells). Figure 4A shows SOCE without NAGly (open circles) and in the presence of NAGly (10  $\mu\text{M}$ , gray down triangles). As already illustrated<sup>9</sup>, NAGly exerts complex actions on neuronal  $\text{Ca}^{2+}$  signalling: i) it induces a release of cations ( $\text{Ca}^{2+}$  and  $\text{Zn}^{2+}$ ) that develops prior to thapsigargin addition (phase ①, Figure 4A); ii) it upregulates the thapsigargin-dependent  $\text{Ca}^{2+}$  release (phase ②); and iii) reduces the amplitude of SOCE (phase ③). Even in the presence of 1  $\mu\text{M}$  Ex26 (gray up triangles) or 10  $\mu\text{M}$  Ki16425 (filled squares, Figure 4A), NAGly elevated the Fura-2 fluorescence on its own (phase ①) and potentiated the thapsigargin-evoked  $\text{Ca}^{2+}$  release (phase ②). The NAGly-induced inhibition of SOCE (phase ③) was also not affected by Ex26 or Ki16425 (Figure 4A). NAGly had however no inhibitory action on the entry of  $\text{Ca}^{2+}$  when added together with BTP2 (open squares, Figure 4A).

The Fura-2  $\text{Ca}^{2+}$  signals (phases ①, ②, ③) observed without NAGly (white bars), with NAGly (gray bars), NAGly+Ki16425 (black bars), NAGly+Ex26 (black/white bars), and NAGly+BTP2 (hatched bars) were analyzed as area under curve (AUC) (Figure 4B). In conclusion, Ki16425 and Ex26 failed to affect the NAGly-evoked  $\text{Ca}^{2+}$  rise (phase ①). These blockers also did not influence the potentiation of the thapsigargin-induced  $\text{Ca}^{2+}$  signal induced by NAGly (phase ②) and the NAGly-dependent depression of SOCE (phase ③). It is proposed that NAGly inhibits a BTP2-sensitive  $\text{Ca}^{2+}$  entry pathway without recruiting LPA or S1P-sensitive receptors.

## Discussion

NAGly inhibits SOCE<sup>20</sup>. This impairment has been observed in every cell type and cell line tested so far like fibroblasts, neurons, EA.hy926 (human endothelial cell line), INS-1 832/13 (rat pancreatic  $\beta$ -cell line), and RBL-2H3 cells (rat basophilic leukemia cell line)<sup>9,20,21</sup>. However, the mechanism by which NAGly alters SOCE is unclear. In the present study we addressed the question of the contribution of lipid sensing GPCRs as targets of NAGly with the aim to gain a better knowledge on neuronal SOCE functioning and regulation. To reach that goal, we took advantage of a recent transcriptomic analysis of the whole murine genome by RNA-seq<sup>22</sup>. This allowed us to consider the mRNA expression of 60 putative lipid sensing GPCRs<sup>26-30</sup>. Overall, transcripts of 14 genes ( $\square$ 25%) were detected. Their abundance varied during embryonic development with 7 genes being induced (Cnr1, Gpr4, Gpr12, Gpr17, Gper1, Gpr34, Adgrb1) and 7 genes being repressed (Lpar1, Lpar2, Lpar4, Lpar6, S1pr1, S1pr2, S1pr3). At E13, age at which cerebral cortices were collected to perform the Ca<sup>2+</sup> imaging experiments<sup>9</sup>, the most abundant mRNAs were those coding for CB<sub>1</sub> and S1P<sub>1</sub> receptors, followed by LPA<sub>2</sub> and LPA<sub>6</sub> receptors. Since the cannabinoid receptor CB<sub>1</sub> does not seem to mediate the NAGly-dependent impairment of SOCE<sup>9</sup>, only the contribution of S1P and LPA receptors in the NAGly-mediated modulation of SOCE was investigated.

Five subtypes of S1P receptors are known (S1P<sub>1-5</sub>). They belong to the group of GPCRs and mediate most of the biological actions of the bioactive sphingolipid S1P<sup>30</sup>. Embryonic cerebral cortices displayed a high mRNA level of S1P<sub>1</sub> receptors that declined during embryonic brain development. In addition, cultured cortical cells expressed functional receptors coupled to the release of Ca<sup>2+</sup> from the ER and sensitive to the S1P<sub>1</sub> antagonist Ex26. These findings are in line with previous reports showing that S1P<sub>1</sub> is the major S1P receptor of the murine embryonic brain, followed by S1P<sub>2</sub> and S1P<sub>3</sub> receptors. It is detected as early as E14, highly expressed in proliferative regions (neurogenic ventricular zone) but its expression decreases at E16 and E18<sup>47</sup>. The activation of S1P<sub>1</sub> receptors is coupled to the mobilization of Ca<sup>2+</sup><sup>33</sup>.

LPA receptors constitute another important family of GPCRs sensitive to bioactive lipids<sup>30,37</sup>. LPA signalling is of particular physiological relevance for the embryonic brain cortex<sup>48</sup>. At E12.5 the most abundant transcripts in the telencephalon are LPA<sub>1</sub>, LPA<sub>2</sub> and LPA<sub>4</sub><sup>35</sup>. In the present work, the main genes expressed at E13 were encoding for LPA<sub>2</sub> and LPA<sub>6</sub>. Moreover, the application of LPA caused the release of Ca<sup>2+</sup> from the ER. These responses were highly sensitive to the LPA<sub>1/3</sub> antagonist Ki16425 but moderately affected by the LPA<sub>2/3</sub> antagonist H2L5186303<sup>30,37</sup>. The pharmacological dissection of the LPA-induced Ca<sup>2+</sup> signalling pointing to LPA<sub>1/3</sub> as the likely receptors responding to LPA is difficult to reconcile with the gene analysis showing that LPA<sub>1</sub> and LPA<sub>3</sub> are, respectively, very weakly expressed and undetected. The pharmacological properties of native LPA receptors of cortical neurons may differ from those of LPA receptors heterogeneously expressed.

After having shown the presence of functional LPA and S1P receptors, their contribution to the NAGly-dependent depression of SOCE was evaluated. The pharmacological blockade of S1P and LPA receptors with Ex26 or Ki16425 did not abolish or attenuate the NAGly-dependent impairment of SOCE. Some cellular responses of NAGly have been shown to be mediated by the orphan receptor GPR55<sup>11</sup>. However, we found no evidence for the presence of significant levels of GPR55 mRNA. Furthermore, the GPR55 agonist AM251<sup>49</sup>, which induces a GPR55-dependent mobilization of Ca<sup>2+</sup> with an EC<sub>50</sub> of  $\approx 0.6 \mu\text{M}$ <sup>50</sup>, fails to evoke any Ca<sup>2+</sup> release when applied to cortical cells at 10  $\mu\text{M}$ . This further suggests that GPR55 does not participate in the NAGly-induced alteration of neuronal Ca<sup>2+</sup> signalling.

In conclusion, our data show that NAGly inhibits a BTP2-sensitive Ca<sup>2+</sup> entry, which is most likely a SOCE. This occurs independently of GPR55, LPA and S1P receptors (present report), and via a mechanism insensitive to the pertussis toxin<sup>9</sup>. It is worth recalling that NAGly regulates voltage-gated Ca<sup>2+</sup> channel activity without acting on GPCRs<sup>8,13</sup>. Although we cannot exclude the possibility that NAGly acts on an orphan lipid sensing GPCR that was not considered in the present study, our report suggests that NAGly disturbs the coupling of the core components of the SOCE machinery (STIM-Orai)<sup>20</sup>. This inhibitory process does not seem to develop in response to an intracellular signalling cascade. These past<sup>9</sup> and present data show that the phytocannabinoid cannabidiol, the endocannabinoid AEA and its derivative NAGly are potent inhibitors of neuronal SOCE. This indicates that NAGly and endocannabinoids are endogenous SOCE modulators, and raises the possibility that the depression of SOCE could play a role in the neuro-behavioural effects of cannabinoids and signalling lipids.

## **Acknowledgements**

The study was supported by a grant from l'Agence Nationale de la Recherche (ANR-16-CE29-0024 to AB). We also acknowledge support from the Centre National de la Recherche Scientifique (CNRS), the Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), the Université de Grenoble Alpes (UGA), and the animal facility platform supported by GRAL, financed within the University Grenoble Alpes graduate school (Ecoles Universitaires de Recherche) CBH-EUR-GS (ANR-17-EURE-0003). We wish to thank Drs C. Blugeon and S. Lemoine from the Institut de Biologie de l'Ecole Normale Supérieure (IBENS, Paris) for their help with the gene analysis. We also appreciate comments on this manuscript prior to submission from Dr J. Gibon (University of British Columbia, Kelowna). We also thank Dr A. Journet, E. Taillebourg and G. Courtois for reading the manuscript.

**Author contribution**

AD, JH and AB performed experiments and analyzed data. AB designed the study and wrote the manuscript.

**Competing Interests' Statement**

The authors declare no competing interests.

## Legends of figures

### Figure 1 mRNA expression of putative lipid sensing GPCRs in the embryonic murine cortex

The data used to plot this graph were extracted from a previous whole-genome transcriptomic analysis<sup>22</sup>. A total of 60 genes encoding for putative lipid sensing GPCRs were selected (see Table 1).

Transcripts of only 14 genes (out of 60) could be detected (e.g. having TPM values  $\geq 2$ ). The graph shows the temporal pattern of the mRNA abundance of these 14 genes at 3 embryonic ages: E11, E13 and E17. Genes that were induced (Cnr1, Gpr4, Gpr12, Gpr17, Gper1, Gpr34, Adgrb1) are shown on the left whereas genes that were repressed (Lpar1, Lpar2, Lpar4, Lpar6, S1pr1, S1pr2, S1pr3) appears on the right. Vertical arrows indicate the 3 most abundant transcripts at E13 (except CB<sub>1</sub>, see text for further details).

### Figure 2 Presence of functional LPA- and S1P-sensitive receptors

The presence of functional LPA and S1P receptors was verified with the fluorescent Ca<sup>2+</sup> probe Fluo-4. In these experiments, cells were maintained in a nominally Ca<sup>2+</sup> free saline. Panels A and C show somatic Fluo-4 signals (F/F<sub>0</sub>) as a function of time in response to 10  $\mu$ M LPA (n=10) (panel A) and 10  $\mu$ M S1P (n=9) (panel C). Panel B shows the LPA-induced Ca<sup>2+</sup> rises measured as area under the curve (AUC) in the absence (white bar, n=10) or presence of H2L5186303 (10  $\mu$ M, n=5), Ki16425 (10  $\mu$ M, n=7), or after the application of thapsigargin (Tg, 200 nM, n=5). \* p<0.05 vs LPA, one-way ANOVA followed by a Bonferroni's *post hoc* test. Panel D shows the Fluo-4 responses (measured as area under the curve, AUC) induced by S1P alone (10  $\mu$ M, n=9), S1P+Ex26 (1  $\mu$ M, n=7), and S1P applied after thapsigargin (Tg, 200 nM, n=5), with \* p<0.05 vs S1P, one-way ANOVA followed by a Bonferroni's *post hoc* test. Antagonists of LPA and S1P receptors were added 4-7 min before time 0 and remained present throughout the recordings. LPA and S1P can stimulate store-released Ca<sup>2+</sup>. Pre-depleting the ER Ca<sup>2+</sup> with Tg prevents any response to LPA or S1P

### Figure 3 Effects of Ex26, Ki16425, and BTP2 on the thapsigargin-evoked Ca<sup>2+</sup> release and SOCE

SOCE responses were analysed with Fura-2. Cells were kept in a nominally Ca<sup>2+</sup>-free medium. ER Ca<sup>2+</sup> stores were depleted with thapsigargin (Tg, 200 nM) before re-introducing external Ca<sup>2+</sup>. The resulting increase in intracellular Ca<sup>2+</sup> is due to Ca<sup>2+</sup> entering via the plasma membrane. Panel A shows somatic Ca<sup>2+</sup> responses (expressed as  $\Delta$  ratio F340/F380) as a function of time, and generated by the sequential addition of Tg (200 nM, horizontal gray bar) followed by the readmission of 2 mM external Ca<sup>2+</sup> (horizontal black bar). Four conditions are shown: without antagonists of LPA and S1P receptors (open circles, n=7), with 1  $\mu$ M Ex26 (gray triangles, n=5), with 10  $\mu$ M Ki16425 (filled squares, n=5), and with 1  $\mu$ M BTP2 (symbols, n=5). When tested, Ex26 (or Ki16425) and BTP2 were added 4-7 and 11-12 min, respectively, before time 0 and were also present during the recordings. One

time point out of 3 is shown. Panel **B** shows the thapsigargin-evoked  $\text{Ca}^{2+}$  release and SOCE measured as area under the curve (AUC). Mean  $\pm$  SEM.

#### **Figure 4 Ex26 and Ki16425 do not reverse the NAGly-induced depression of SOCE**

Panel **A** shows Fura-2 responses ( $\Delta$  ratio F340/F380) as a function of time before, during the transient application of 200 nM thapsigargin (Tg, horizontal gray bar) to cells kept in a nominally  $\text{Ca}^{2+}$ -free medium (depletion of ER  $\text{Ca}^{2+}$  stores, phase ②), and after the readmission of 2 mM external  $\text{Ca}^{2+}$  (horizontal black bar) (SOCE, phase ③). Open circles: control conditions (without NAGly) (n=7). When indicated, 10  $\mu\text{M}$  NAGly was added (vertical arrow) prior to thapsigargin. This elevated the Fura-2 fluorescence (phase ①) (black triangles, n=6). Similar experiments were conducted in the presence of NAGly + 10  $\mu\text{M}$  Ki16425 (gray squares, n=5), NAGly + 10  $\mu\text{M}$  Ex26 (open triangles, n=4), and NAGly + 1  $\mu\text{M}$  BTP2 (symbol, n=3). As in figure 3, Ki16425 (or Ex26) and BTP2 were added 4-7 and 11-12 min before time 0 and remained present throughout the recordings. One time point out of 3 is shown. Mean  $\pm$  SEM.

Panel **B**: Area under curve (AUC) measurements of Fura-2 signals under the different conditions tested. Three phases were considered:  $\text{Ca}^{2+}$  signals prior to the addition of thapsigargin (phase ①), the thapsigargin-induced  $\text{Ca}^{2+}$  release (phase ②) and SOCE (phase ③). \*  $p < 0.05$  vs NAGly-untreated cells, one-way ANOVA followed by a Bonferroni's *post hoc* test.

## References

- 1 Huang, S. M. *et al.* Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain. *The Journal of biological chemistry* **276**, 42639-42644, doi:10.1074/jbc.M107351200 (2001).
- 2 Bradshaw, H. B. *et al.* The endocannabinoid anandamide is a precursor for the signaling lipid N-arachidonoyl glycine by two distinct pathways. *BMC biochemistry* **10**, 14, doi:10.1186/1471-2091-10-14 (2009).
- 3 Barbara, G. *et al.* T-type calcium channel inhibition underlies the analgesic effects of the endogenous lipoamino acids. *J Neurosci* **29**, 13106-13114, doi:10.1523/JNEUROSCI.2919-09.2009 (2009).
- 4 Staton, P. C. *et al.* The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. *Pain* **139**, 225-236, doi:10.1016/j.pain.2008.04.006 (2008).
- 5 Deliu, E. *et al.* The Lysophosphatidylinositol Receptor GPR55 Modulates Pain Perception in the Periaqueductal Gray. *Molecular pharmacology* **88**, 265-272, doi:10.1124/mol.115.099333 (2015).
- 6 Burstein, S. H. The cannabinoid acids, analogs and endogenous counterparts. *Bioorganic & medicinal chemistry* **22**, 2830-2843, doi:10.1016/j.bmc.2014.03.038 (2014).
- 7 Jeong, H. J., Vandenberg, R. J. & Vaughan, C. W. N-arachidonoyl-glycine modulates synaptic transmission in superficial dorsal horn. *British journal of pharmacology* **161**, 925-935, doi:10.1111/j.1476-5381.2010.00935.x (2010).
- 8 Chemin, J., Cazade, M. & Lory, P. Modulation of T-type calcium channels by bioactive lipids. *Pflugers Arch* **466**, 689-700, doi:10.1007/s00424-014-1467-5 (2014).
- 9 Bouron, A. Phyto and endocannabinoids exert complex actions on calcium and zinc signaling in mouse cortical neurons. *Biochem Pharmacol* **152**, 244-251, doi:10.1016/j.bcp.2018.04.003 (2018).
- 10 McHugh, D. *et al.* N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. *BMC neuroscience* **11**, 44, doi:10.1186/1471-2202-11-44 (2010).
- 11 Console-Bram, L. *et al.* N-arachidonoyl glycine, another endogenous agonist of GPR55. *Biochemical and biophysical research communications* **490**, 1389-1393, doi:10.1016/j.bbrc.2017.07.038 (2017).
- 12 Oh, D. Y. *et al.* Identification of farnesyl pyrophosphate and N-arachidonoylglycine as endogenous ligands for GPR92. *The Journal of biological chemistry* **283**, 21054-21064, doi:10.1074/jbc.M708908200 (2008).
- 13 Lu, V. B., Puhl, H. L., 3rd & Ikeda, S. R. N-Arachidonoyl glycine does not activate G protein-coupled receptor 18 signaling via canonical pathways. *Mol Pharmacol* **83**, 267-282, doi:10.1124/mol.112.081182 (2013).
- 14 Bondarenko, A. I. *et al.* N-Arachidonoyl glycine suppresses Na(+)/Ca(2)(+) exchanger-mediated Ca(2)(+) entry into endothelial cells and activates BK(Ca) channels independently of GPCRs. *British journal of pharmacology* **169**, 933-948, doi:10.1111/bph.12180 (2013).
- 15 Putney, J. W. *et al.* The functions of store-operated calcium channels. *Biochimica et biophysica acta. Molecular cell research* **1864**, 900-906, doi:10.1016/j.bbamcr.2016.11.028 (2017).
- 16 Parekh, A. B. Store-operated CRAC channels: function in health and disease. *Nat Rev Drug Discov* **9**, 399-410, doi:10.1038/nrd3136 (2010).
- 17 Yeung, P. S., Yamashita, M. & Prakriya, M. Pore opening mechanism of CRAC channels. *Cell Calcium* **63**, 14-19, doi:10.1016/j.ceca.2016.12.006 (2017).
- 18 Hogan, P. G. & Rao, A. Store-operated calcium entry: Mechanisms and modulation. *Biochem Biophys Res Commun* **460**, 40-49, doi:10.1016/j.bbrc.2015.02.110 (2015).
- 19 Stathopulos, P. B. & Ikura, M. Structure and function of endoplasmic reticulum STIM calcium sensors. *Current topics in membranes* **71**, 59-93, doi:10.1016/B978-0-12-407870-3.00003-2 (2013).

- 20 Deak, A. T. *et al.* The endocannabinoid N-arachidonoyl glycine (NAGly) inhibits store-operated Ca<sup>2+</sup> entry by preventing STIM1-Orai1 interaction. *J Cell Sci* **126**, 879-888, doi:10.1242/jcs.118075 (2013).
- 21 Nelson, H. A., Leech, C. A., Kopp, R. F. & Roe, M. W. Interplay between ER Ca(2+) Binding Proteins, STIM1 and STIM2, Is Required for Store-Operated Ca(2+) Entry. *International journal of molecular sciences* **19**, doi:10.3390/ijms19051522 (2018).
- 22 Hasna, J., Bohic, S., Lemoine, S., Blugeon, C. & Bouron, A. Zinc Uptake and Storage During the Formation of the Cerebral Cortex in Mice. *Mol Neurobiol* **56**, 6928-6940, doi:10.1007/s12035-019-1581-7 (2019).
- 23 Gibon, J. *et al.* The antidepressant hyperforin increases the phosphorylation of CREB and the expression of TrkB in a tissue-specific manner. *Int J Neuropsychopharmacol* **16**, 189-198 (2013).
- 24 Chauvet, S. *et al.* Pharmacological Characterization of the Native Store-Operated Calcium Channels of Cortical Neurons from Embryonic Mouse Brain. *Frontiers in Pharmacology* **7**, doi:10.3389/fphar.2016.00486 (2016).
- 25 Gruszczynska-Biegala, J., Sladowska, M. & Kuznicki, J. AMPA Receptors Are Involved in Store-Operated Calcium Entry and Interact with STIM Proteins in Rat Primary Cortical Neurons. *Frontiers in cellular neuroscience* **10**, 251, doi:10.3389/fncel.2016.00251 (2016).
- 26 Im, D. S. Discovery of new G protein-coupled receptors for lipid mediators. *Journal of lipid research* **45**, 410-418, doi:10.1194/jlr.R300006-JLR200 (2004).
- 27 Im, D. S. Intercellular Lipid Mediators and GPCR Drug Discovery. *Biomolecules & therapeutics* **21**, 411-422, doi:10.4062/biomolther.2013.080 (2013).
- 28 Irving, A. *et al.* Cannabinoid Receptor-Related Orphan G Protein-Coupled Receptors. *Advances in pharmacology* **80**, 223-247, doi:10.1016/bs.apha.2017.04.004 (2017).
- 29 Pertwee, R. G. *et al.* International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB(1) and CB(2). *Pharmacological reviews* **62**, 588-631, doi:10.1124/pr.110.003004 (2010).
- 30 Kihara, Y., Maceyka, M., Spiegel, S. & Chun, J. Lysophospholipid receptor nomenclature review: IUPHAR Review 8. *Br J Pharmacol* **171**, 3575-3594, doi:10.1111/bph.12678 (2014).
- 31 Wagner, G. P., Kin, K. & Lynch, V. J. A model based criterion for gene expression calls using RNA-seq data. *Theory in biosciences = Theorie in den Biowissenschaften* **132**, 159-164, doi:10.1007/s12064-013-0178-3 (2013).
- 32 Sheskin, T., Hanus, L., Slager, J., Vogel, Z. & Mechoulam, R. Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. *Journal of medicinal chemistry* **40**, 659-667, doi:10.1021/jm960752x (1997).
- 33 Mattie, M., Brooker, G. & Spiegel, S. Sphingosine-1-phosphate, a putative second messenger, mobilizes calcium from internal stores via an inositol trisphosphate-independent pathway. *The Journal of biological chemistry* **269**, 3181-3188 (1994).
- 34 Shirakawa, H. *et al.* Sphingosine-1-phosphate induces Ca(2+) signaling and CXCL1 release via TRPC6 channel in astrocytes. *Glia* **65**, 1005-1016, doi:10.1002/glia.23141 (2017).
- 35 Dubin, A. E., Herr, D. R. & Chun, J. Diversity of lysophosphatidic acid receptor-mediated intracellular calcium signaling in early cortical neurogenesis. *J Neurosci* **30**, 7300-7309, doi:10.1523/JNEUROSCI.6151-09.2010 (2010).
- 36 Hildebrandt, J. P. & Hildebrandt, P. Lysophosphatidic acid depletes intracellular calcium stores different from those mediating capacitative calcium entry in C6 rat glioma cells. *Glia* **19**, 67-73 (1997).
- 37 Yung, Y. C., Stoddard, N. C. & Chun, J. LPA receptor signaling: pharmacology, physiology, and pathophysiology. *J Lipid Res* **55**, 1192-1214, doi:10.1194/jlr.R046458 (2014).
- 38 Im, D. S. Pharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors. *Acta pharmacologica Sinica* **31**, 1213-1222, doi:10.1038/aps.2010.135 (2010).
- 39 Stoddard, N. C. & Chun, J. Promising pharmacological directions in the world of lysophosphatidic Acid signaling. *Biomolecules & therapeutics* **23**, 1-11, doi:10.4062/biomolther.2014.109 (2015).
- 40 Chun, J., Hla, T., Lynch, K. R., Spiegel, S. & Moolenaar, W. H. International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. *Pharmacol Rev* **62**, 579-587, doi:10.1124/pr.110.003111 (2010).

- 41 Cahalan, S. M. *et al.* Sphingosine 1-phosphate receptor 1 (S1P(1)) upregulation and amelioration of experimental autoimmune encephalomyelitis by an S1P(1) antagonist. *Mol Pharmacol* **83**, 316-321, doi:10.1124/mol.112.082958 (2013).
- 42 Bouron, A., Altafaj, X., Boisseau, S. & De Waard, M. A store-operated Ca<sup>2+</sup> influx activated in response to the depletion of thapsigargin-sensitive Ca<sup>2+</sup> stores is developmentally regulated in embryonic cortical neurons from mice. *Brain Res Dev Brain Res* **159**, 64-71 (2005).
- 43 Bouron, A., Boisseau, S., De Waard, M. & Peris, L. Differential down-regulation of voltage-gated calcium channel currents by glutamate and BDNF in embryonic cortical neurons. *Eur J Neurosci* **24**, 699-708 (2006).
- 44 Dubin, A. E., Bahnson, T., Weiner, J. A., Fukushima, N. & Chun, J. Lysophosphatidic Acid Stimulates Neurotransmitter-Like Conductance Changes that Precede GABA and L-Glutamate in Early, Presumptive Cortical Neuroblasts. *J. Neurosci.* **19**, 1371-1381 (1999).
- 45 Ishikawa, J. *et al.* A Pyrazole Derivative, YM-58483, Potently Inhibits Store-Operated Sustained Ca<sup>2+</sup> Influx and IL-2 Production in T Lymphocytes. *J Immunol* **170**, 4441-4449 (2003).
- 46 Zitt, C. *et al.* Potent inhibition of Ca<sup>2+</sup> release-activated Ca<sup>2+</sup> channels and T-lymphocyte activation by the pyrazole derivative BTP2. *J Biol Chem* **279**, 12427-12437, doi:10.1074/jbc.M309297200 (2004).
- 47 McGiffert, C., Contos, J. J., Friedman, B. & Chun, J. Embryonic brain expression analysis of lysophospholipid receptor genes suggests roles for s1p(1) in neurogenesis and s1p(1-3) in angiogenesis. *FEBS letters* **531**, 103-108 (2002).
- 48 Yung, Y. C., Stoddard, N. C., Mirendil, H. & Chun, J. Lysophosphatidic Acid signaling in the nervous system. *Neuron* **85**, 669-682, doi:10.1016/j.neuron.2015.01.009 (2015).
- 49 Ryberg, E. *et al.* The orphan receptor GPR55 is a novel cannabinoid receptor. *British journal of pharmacology* **152**, 1092-1101, doi:10.1038/sj.bjp.0707460 (2007).
- 50 Henstridge, C. M. *et al.* The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca<sup>2+</sup> signaling and NFAT activation. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology* **23**, 183-193, doi:10.1096/fj.08-108670 (2009).

**Table 1:** List of selected 60 murine genes encoding for lipid sensing G protein-coupled receptors (GPCRs)

<i>EnsemblID</i>	<i>Gene name</i>	<i>other names</i>	<i>Gene description</i>
ENSMUSG00000044288	Cnr1		cannabinoid receptor 1
ENSMUSG00000062585	Cnr2		cannabinoid receptor 2
ENSMUSG00000046856	Gpr1		G protein-coupled receptor 1
ENSMUSG00000046856	Gpr1		G protein-coupled receptor 1
ENSMUSG00000044317	Gpr4		G protein-coupled receptor 4
ENSMUSG00000046922	Gpr6		G protein-coupled receptor 6
ENSMUSG00000041468	Gpr12		G-protein coupled receptor 12
ENSMUSG00000052229	Gpr17		G protein-coupled receptor
ENSMUSG00000050350	Gpr18		G protein-coupled receptor 18
ENSMUSG00000053647	Gpr30	Gper1	G protein-coupled estrogen receptor 1
ENSMUSG00000071311	Gpr31b		G protein-coupled receptor 31
ENSMUSG00000040229	Gpr34	P2Y12	G protein-coupled receptor 34
ENSMUSG00000026271	Gpr35		G protein-coupled receptor 35
ENSMUSG00000049608	Gpr55		G protein-coupled receptor 55
ENSMUSG00000040372	Gpr63		G protein-coupled receptor 63
ENSMUSG00000021886	Gpr65	TDAG8	G-protein coupled receptor 65
ENSMUSG00000047415	Gpr68	OGR1	G protein-coupled receptor 68
ENSMUSG00000049241	gpr81	Hcar1	hydrocarboxylic acid receptor 1
ENSMUSG00000063234	Gpr84		G protein-coupled receptor 84
ENSMUSG00000051431	Gpr87		G protein-coupled receptor 87
ENSMUSG00000045502	Gpr109A	Hcar2	hydroxycarboxylic acid receptor 2
ENSMUSG00000051209	Gpr119		G-protein coupled receptor 119
ENSMUSG00000064272	Gpr131	Gpbar1	G protein-coupled bile acid receptor 1
ENSMUSG00000021298	Gpr132		G protein-coupled receptor 132
ENSMUSG00000073008	Gpr174		G protein-coupled receptor 174
ENSMUSG00000051212	Gpr183		G protein-coupled receptor 183
ENSMUSG00000034730	Adgrb1	Bai1	adhesion G protein-coupled receptor B1
ENSMUSG00000046908	Ltb4r1		leukotriene B4 receptor 1
ENSMUSG00000040432	Ltb4r2		leukotriene B4 receptor 2
ENSMUSG00000052821	Cysltr1		cysteinyl leukotriene receptor 1
ENSMUSG00000033470	Cysltr2		cysteinyl leukotriene receptor 2

ENSMUSG00000071489	Ptgdr		prostaglandin D receptor
ENSMUSG00000034117	Ptgdr2		prostaglandin D2 receptor 2
ENSMUSG00000019464	Ptger1		prostaglandin E receptor 1
ENSMUSG00000037759	Ptger2		prostaglandin E receptor 2 (subtype EP2)
ENSMUSG00000040016	Ptger3		prostaglandin E receptor 3 (subtype EP3)
ENSMUSG00000039942	Ptger4		prostaglandin E receptor 4 (subtype EP4)
ENSMUSG00000044453	Ffar1		free fatty acid receptor 1
ENSMUSG00000051314	Ffar2		free fatty acid receptor 2
ENSMUSG00000051314	Ffar2		free fatty acid receptor 2
ENSMUSG00000054200	Ffar4		free fatty acid receptor 4
ENSMUSG00000028036	Ptgfr		prostaglandin F receptor
ENSMUSG00000052270	Fpr2		formyl peptide receptor 2
ENSMUSG00000043017	Ptgir		prostaglandin I receptor
ENSMUSG00000038668	Lpar1		lysophosphatidic acid receptor 1
ENSMUSG00000031861	Lpar2		lysophosphatidic acid receptor 2
ENSMUSG00000036832	Lpar3		lysophosphatidic acid receptor 3
ENSMUSG00000049929	Lpar4		lysophosphatidic acid receptor 4
ENSMUSG00000067714	Lpar5		lysophosphatidic acid receptor 5
ENSMUSG00000033446	Lpar6		lysophosphatidic acid receptor 6
ENSMUSG00000044819	Gpr80	Oxgr1, Gpr99, P2Y15	oxoglutarate (alpha-ketoglutarate) receptor 1
ENSMUSG00000056529	Ptafr		platelet-activating factor receptor
ENSMUSG00000050921	P2ry10		purinergic receptor P2Y, G-protein coupled 10
ENSMUSG00000045092	S1pr1		sphingosine-1-phosphate receptor 1
ENSMUSG00000043895	S1pr2		sphingosine-1-phosphate receptor 2
ENSMUSG00000067586	S1pr3		sphingosine-1-phosphate receptor 3
ENSMUSG00000044199	S1pr4		sphingosine-1-phosphate receptor 4
ENSMUSG00000045087	S1pr5		sphingosine-1-phosphate receptor 5
ENSMUSG00000027762	Sucnr1		succinate receptor 1
ENSMUSG00000034881	Tbxa2r		thromboxane A2 receptor